Charles Ferté

7.8k total citations · 3 hit papers
78 papers, 4.3k citations indexed

About

Charles Ferté is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Charles Ferté has authored 78 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 22 papers in Cancer Research. Recurrent topics in Charles Ferté's work include Cancer Genomics and Diagnostics (21 papers), Radiomics and Machine Learning in Medical Imaging (18 papers) and Lung Cancer Treatments and Mutations (15 papers). Charles Ferté is often cited by papers focused on Cancer Genomics and Diagnostics (21 papers), Radiomics and Machine Learning in Medical Imaging (18 papers) and Lung Cancer Treatments and Mutations (15 papers). Charles Ferté collaborates with scholars based in France, United States and Spain. Charles Ferté's co-authors include Jean‐Charles Soria, Christophe Massard, Stéphane Champiat, Laurent Dercle, Aurélien Marabelle, Antoine Hollebecque, Samy Ammari, Éric Deutsch, Charlotte Robert and Roger Sun and has published in prestigious journals such as Journal of Clinical Oncology, Bioinformatics and PLoS ONE.

In The Last Decade

Charles Ferté

74 papers receiving 4.2k citations

Hit Papers

Hyperprogressive Disease ... 2016 2026 2019 2022 2016 2018 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
    2016 867 citations Stéphane Champiat, Laurent Dercle et al. Clinical Cancer Research profile →
  2. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
    2018 825 citations Roger Sun, Elaine Johanna Limkin et al. profile →
  3. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
    2017 570 citations Elaine Johanna Limkin, Roger Sun et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Charles Ferté 2.5k 1.6k 1.5k 617 598 78 4.3k
Samy Ammari 2.7k 1.1× 1.9k 1.2× 1.4k 1.0× 524 0.8× 666 1.1× 114 4.6k
Robert Ford 2.2k 0.9× 926 0.6× 1.4k 1.0× 621 1.0× 463 0.8× 20 3.7k
Laurent Dercle 2.6k 1.0× 2.8k 1.8× 1.6k 1.0× 598 1.0× 512 0.9× 127 5.0k
Christina Messiou 2.1k 0.9× 1.7k 1.1× 2.5k 1.7× 597 1.0× 307 0.5× 180 5.8k
Yvette L. Kasamon 2.1k 0.9× 2.3k 1.4× 1.1k 0.8× 357 0.6× 1.3k 2.1× 99 5.9k
Caroline Caramella 4.6k 1.9× 831 0.5× 2.2k 1.5× 1.2k 2.0× 874 1.5× 137 6.3k
Hui Zhu 1.7k 0.7× 580 0.4× 1.1k 0.7× 395 0.6× 443 0.7× 152 3.7k
Heather A. Jacene 1.7k 0.7× 3.3k 2.1× 1.8k 1.2× 699 1.1× 195 0.3× 152 5.6k
William A. Hall 1.5k 0.6× 1.2k 0.8× 1.7k 1.1× 750 1.2× 152 0.3× 199 3.9k
Timothy Akhurst 1.9k 0.8× 1.4k 0.9× 1.4k 0.9× 919 1.5× 172 0.3× 75 4.4k

Countries citing papers authored by Charles Ferté

Since Specialization
Citations

This map shows the geographic impact of Charles Ferté's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Ferté with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Ferté more than expected).

Fields of papers citing papers by Charles Ferté

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Ferté. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Ferté. The network helps show where Charles Ferté may publish in the future.

Co-authorship network of co-authors of Charles Ferté

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Ferté. A scholar is included among the top collaborators of Charles Ferté based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Ferté. Charles Ferté is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Franzoi, Maria Alice, Arlindo R. Ferreira, Antoine Lemaire, et al.. (2024). Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium. The Lancet Regional Health - Europe. 44. 101005–101005. 15 indexed citations
2.
Minvielle, Étienne, Philippe Aegerter, Marie Ferrua, et al.. (2024). The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling. Journal of Medical Internet Research. 27. e66275–e66275.
3.
Tran, Ben, Mark Voskoboynik, Johanna C. Bendell, et al.. (2024). A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy. 16(11). 759–774. 5 indexed citations
4.
5.
Gelli, Maximiliano, Christophe Desterke, Valérie Boige, et al.. (2023). Primary Colorectal Tumor Displays Differential Genomic Expression Profiles Associated with Hepatic and Peritoneal Metastases. Cancers. 15(17). 4418–4418. 1 indexed citations
6.
Limkin, Elaine Johanna, Sylvain Reuzé, Alexandre Carré, et al.. (2019). The complexity of tumor shape, spiculatedness, correlates with tumor radiomic shape features. Scientific Reports. 9(1). 4329–4329. 78 indexed citations
7.
Claret, Laurent, Jin Y. Jin, Charles Ferté, et al.. (2018). A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics. Clinical Cancer Research. 24(14). 3292–3298. 53 indexed citations
8.
Clémenson, Céline, Cyrus Chargari, Michele Mondini, et al.. (2017). The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy. Molecular Cancer Therapeutics. 16(10). 2107–2119. 24 indexed citations
9.
Massard, Christophe, Isabelle Borget, Françoise Farace, et al.. (2017). RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study. European Journal of Cancer. 83. 185–193. 18 indexed citations
10.
11.
Champiat, Stéphane, Laurent Dercle, Samy Ammari, et al.. (2016). Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clinical Cancer Research. 23(8). 1920–1928. 867 indexed citations breakdown →
12.
Ferté, Charles, Andrew D. Trister, Erich Huang, et al.. (2013). Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology. Clinical Cancer Research. 19(16). 4315–4325. 33 indexed citations
13.
Guinney, Justin, Charles Ferté, Jonathan R. Dry, et al.. (2013). Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. Clinical Cancer Research. 20(1). 265–272. 30 indexed citations
14.
Ferté, Charles, Yohann Loriot, Céline Clémenson, et al.. (2013). IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy. Molecular Cancer Therapeutics. 12(7). 1213–1222. 42 indexed citations
15.
Ferté, Charles, Antoine Hollebecque, Serge Koscielny, et al.. (2013). Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials. Clinical Cancer Research. 20(1). 246–252. 130 indexed citations
16.
Olmos, David, Charles Ferté, Philippe A. Cassier, et al.. (2012). Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models. Critical Reviews in Oncology/Hematology. 83(2). 242–248. 19 indexed citations
17.
Chargari, Cyrus, et al.. (2011). Ciblage pharmacologique de Mdm2 : bases biologiques et perspectives de radiosensibilisation. Cancer/Radiothérapie. 15(4). 316–322. 1 indexed citations
18.
Ferté, Charles, Angélo Paci, Aïcha Goubar, et al.. (2011). Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues. European Journal of Cancer. 47(15). 2249–2255. 36 indexed citations
19.
Ferté, Charles, et al.. (2009). Équipoise clinique et études cliniques randomisées en cancérologie. Bulletin du Cancer. 96(6). 727–731.
20.
Penel, Nicolas, Nicolás Isambert, Pierre Leblond, et al.. (2009). “Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents. Investigational New Drugs. 27(6). 552–556. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samy Ammari Breakdown of academic impact, for papers by Robert Ford Breakdown of academic impact, for papers by Laurent Dercle Breakdown of academic impact, for papers by Christina Messiou Breakdown of academic impact, for papers by Yvette L. Kasamon Breakdown of academic impact, for papers by Caroline Caramella Breakdown of academic impact, for papers by Hui Zhu Breakdown of academic impact, for papers by Heather A. Jacene Breakdown of academic impact, for papers by William A. Hall Breakdown of academic impact, for papers by Timothy Akhurst
Rankless by CCL
2026